Financial News · Live Terminal

Page 504 of 516

AlphaMena Lowers Seera Group PT, Keeps Add Rating

AlphaMena on Monday reduced its price target for travel agencies operator Seera Group (SASE:1810) to 25.50 Saudi riyals from 28.90 riyals, with an unchanged add rating.

SASE:1810

Research162d ago

Morningstar Begins Flughafen Zürich's Coverage at Buy

Morningstar on Monday started its coverage of Zurich Airport operator Flughafen Zürich (FHZN.SW) with a buy rating and a price target of 280.00 francs.

$FHZN.SW

Research162d ago

Citi Downgrades Nexi to Neutral Rating, Cuts PT

Citi on Tuesday downgraded payment technology company Nexi (NEXI.MI) to neutral from buy and decreased its price target to 3.40 euros from 5 euros.

$NEXI.MI

Research162d ago

Celestica Price Target Raised to US$425 at CIBC

CIBC Capital Markets raised its price target on Celestica Inc. (CLS.TO, CLS) to US$425 from US$360.Analyst Todd Coupland maintained an Outperformer rating on shares of the Canadian electronics manufacturing services company ahead of its fiscal Q1 results on April 27."We continue to view management's guidance - and current FactSet consensus for Q1 and 2026 - as conservative, reflecting improved visibility into capex plans at key hyperscalers (GOOGL, META, AMZN) and OpenAI," Coupland said in a note to clients."Since March 2022, results have exceeded consensus by an average of ~5% on revenue and ~10% on EPS," the analyst said. "Notably, the 2025 results were ~20% higher than the initial Outlook provided in October 2024.""Recent announcements suggest this trend has continued and is pulling forward customer demand from 2027 into 2026, supporting our positive thesis," Coupland said."We raised our target multiples for Celestica to reflect improved visibility to upward revisions in AI datacentre capex spending from significantly improved model performance."

$CLS$CLS.TO

Research162d ago

Argus Initiates Coverage on AppLovin With Buy Rating, $520 Price Target

AppLovin (APP) has an average rating of Buy and mean price target of $652.68, according to analysts polled by FactSet.

$APP

Research162d ago

Eldorado Gold Price Target Lowered to US$40 at TD

TD Securities lowered its price target on Eldorado Gold Corp. (ELD.TO, EGO) to US$40 from US$45 on Tuesday.Analyst Steven Green maintained a Hold rating on shares of the Canadian gold and base metals producer."We have updated our model to reflect EGO's acquisition of Foran Mining Corp. (FOM.TO), which is nearing close," Green said in a note to clients."While the transaction moves the centre of gravity toward Canada, improving the geopolitical risk profile, we view the deal as relatively expensive at ~1.5x NAV and near-term dilutive," the analyst said."We expect execution overlap with Skouries and limited near-term FCF to weigh on sentiment."

$EGO$ELD.TO

Research162d ago

Research Alert: Wfc Q1 2026 Results: Earnings Miss On Weaker-than-expected Net Interest Income

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:WFC posted mixed Q1 2026 results with operating EPS of $1.56 vs. $1.28 the prior year, missing consensus by $0.04 due to weaker-than-expected 5% Y/Y net interest income growth and 20 bps margin contraction to 2.47%. Balance sheet activity was excellent with loan growth accelerating to 10% Y/Y reaching $996B and deposits rising 6% Y/Y to $1.415B, capitalizing on post-asset cap removal opportunities. We expect this loan growth momentum to continue through 2026, noting balances rose just 1% per quarter in 2025. Fee income grew healthy 8% Y/Y due to investment advisory fees (+11%) and modest investment banking growth (+3%). Credit quality remained stable with net charge-offs at 0.45% despite 22% Y/Y increase in provisions to $1.1B, primarily reflecting higher loan balances rather than deteriorating trends. Operational efficiency improved with the efficiency ratio reaching 67% vs 69% prior year, while capital deployment continued with $4.0B in share repurchases, though the CET1 ratio declined to 10.3% from 11.1%.

$WFC

Research162d ago

Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118

Revvity (RVTY) has an average rating of overweight and mean price target of $113, according to analysts polled by FactSet.

$RVTY

Research162d ago

BofA Securities Downgrades Omega Healthcare Investors to Underperform From Neutral, Price Target is $46

Omega Healthcare Investors (OHI) has an average rating of overweight and mean price target of $49.38, according to analysts polled by FactSet.

$OHI

Research162d ago

Piper Sandler Downgrades Monday.com to Neutral From Overweight, Adjusts Price Target to $85 From $100

Monday.com (MNDY) has an average rating of overweight and mean price target of $111.96, according to analysts polled by FactSet.

$MNDY

Research162d ago

JPMorgan Downgrades GFL Environmental to Underweight From Neutral

GFL Environmental Inc (GFL) has an average rating of overweight and mean price target of CA$74.77, according to analysts polled by FactSet.

$GFL

Research162d ago

Goldman Sachs Downgrades Ero Copper to Neutral From Buy, Adjusts Price Target to CA$42.77 From CA$45.85

Ero Copper (ERO) has an average rating of overweight and mean price target of CA$48.92, according to analysts polled by FactSet.

$ERO

Research162d ago

Barclays Downgrades QIAGEN to Equalweight From Overweight, Adjusts Price Target to $44 From $48

QIAGEN (QGEN) has an average rating of overweight and mean price target of $54.01, according to analysts polled by FactSet.

$QGEN

Research162d ago

Research Alert: Jnj Q1 Results Beat Expectations, Raises 2026 Outlook

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:JNJ delivered solid Q1 2026 results with sales growth of 9.9% Y/Y to $24.1B, beating expectations. Adjusted EPS of $2.70 declined from $2.77 prior year but exceeded consensus estimate of $2.68. Strong oncology execution drove Innovative Medicine growth of 11.2% Y/Y to $15.4B, with key Oncology drugs, DARZALEX achieving $4.0B (+22.5% Y/Y) and CARVYKTI reaching $597M (+62.1% Y/Y), helping offset STELARA erosion ($656M, -59.7% Y/Y), as biosimilar competition intensified. Management raised the 2026 guidance to $100.8B sales and $11.55 adjusted EPS, reflecting confidence in the growth trajectory, in our view. We think JNJ's robust pipeline, including key Q1 approvals like ICOTYDE the first-line oral treatment for plaque psoriasis, positions the company well for its transformation into a higher-growth enterprise. With strong franchise execution and multiple growth drivers across oncology and MedTech, we believe JNJ can navigate near-term headwinds while delivering on its path to double-digit growth by decade-end.

$JNJ

Research162d ago

Correction: Piper Sandler Downgrades Asana to Neutral From Overweight, Cuts Price Target to $7 From $9

(Corrected the headline).Asana (ASAN) has an average rating of hold and mean price target of $9.90, according to analysts polled by FactSet.

$ASAN

Research162d ago

Research Alert: Jpm Delivers Earnings And Revenue Beat In Q1 2026

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:JPM delivered exceptional Q1 2026 results with EPS of $5.94 (+17% Y/Y, +28% Q/Q) and net income of $16.5B (+13% Y/Y, +27% Q/Q), with managed revenue of $50.5B (+10% Y/Y) demonstrating strength across all segments. Strong ROE of 19% and ROTCE of 23% validated our investment thesis around capital markets positioning, with record CIB results including Markets revenue of $11.6B (+20% Y/Y) and Investment Banking fees of $2.9B (+28% Y/Y). Management guided 2026 firmwide NII to $103B and adjusted expenses to $105B while maintaining cautious outlook on geopolitical tensions and economic uncertainties. We believe JPM's diversified business model and fortress-like balance sheet with CET1 of 14.5% position it well to navigate complex market conditions ahead. In our view, the bank's ability to generate substantial capital returns of $13.0B while maintaining stable credit quality supports future outperformance, though we expect prudent management given ongoing geopolitical risks. Tangible book value was $108.87, up 8% Y/Y.

$JPM

Research162d ago

Goldman Sachs Downgrades Innoviz Technologies to Neutral From Buy, Adjusts Price Target to $0.75 From $1.25

$INVZ

Research162d ago

BNP Paribas Downgrades Barclays to Neutral From Outperform, Adjusts Price Target to $26 From $29.20

Barclays (BCS) has an average rating of overweight and mean price target of $29.29, according to analysts polled by FactSet.

$BCS

Research162d ago

Deutsche Bank Upgrades General Motors to Buy From Hold, Lifts Price Target to $90 From $83

General Motors (GM) has an average rating of overweight and mean price target of $94.92, according to analysts polled by FactSet.

$GM

Research162d ago

BNP Paribas Downgrades HSBC to Neutral From Outperform, Adjusts Price Target to $97 From $100.50

$HSBC

Showing 10061-10080 of 10301